• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapeutic effect of intravitreal anti-VEGF drugs on retinal neovascularization in diabetic retinopathy.

作者信息

Jiang Guangwei, Han Xue, Qiao Kun, Liu Shu

机构信息

Department of Ophtalmology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.

Department of Ophtalmology, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China -

出版信息

Minerva Med. 2024 Apr;115(2):218-220. doi: 10.23736/S0026-4806.22.07943-5. Epub 2022 Jul 15.

DOI:10.23736/S0026-4806.22.07943-5
PMID:35838253
Abstract
摘要

相似文献

1
Therapeutic effect of intravitreal anti-VEGF drugs on retinal neovascularization in diabetic retinopathy.玻璃体内抗血管内皮生长因子药物对糖尿病视网膜病变视网膜新生血管的治疗作用。
Minerva Med. 2024 Apr;115(2):218-220. doi: 10.23736/S0026-4806.22.07943-5. Epub 2022 Jul 15.
2
A Novel Treatment for Proliferative Diabetic Retinopathy: Anti-Vascular Endothelial Growth Factor Therapy.增殖性糖尿病视网膜病变的一种新型治疗方法：抗血管内皮生长因子疗法。
JAMA Ophthalmol. 2016 Jan;134(1):13-4. doi: 10.1001/jamaophthalmol.2015.5079.
3
Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).单次玻璃体内注射贝伐单抗（阿瓦斯汀）后增生性糖尿病视网膜病变中严重的视盘新生血管迅速消退
Clin Exp Ophthalmol. 2006 Nov;34(8):802-3. doi: 10.1111/j.1442-9071.2006.01378.x.
4
A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.一种用于开发持续抗 VEGF 疗法的新型持续性视网膜新生血管模型。
Exp Eye Res. 2018 Sep;174:98-106. doi: 10.1016/j.exer.2018.05.027. Epub 2018 May 28.
5
Transient regression of new vessels after anti-vascular endothelial growth factor monotherapy in proliferative diabetic retinopathy.增殖性糖尿病视网膜病变患者接受抗血管内皮生长因子单药治疗后新生血管的短暂消退
Clin Exp Optom. 2024 Jul;107(5):587-588. doi: 10.1080/08164622.2023.2199142. Epub 2023 Apr 20.
6
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.私人保险和医疗保险优势计划患者眼科中抗血管内皮生长因子使用的趋势。
Ophthalmology. 2017 Mar;124(3):352-358. doi: 10.1016/j.ophtha.2016.10.036. Epub 2016 Nov 24.
7
Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.接受全视网膜光凝与玻璃体内抗血管内皮生长因子治疗后随访丢失的增生性糖尿病视网膜病变眼的结局。
Ophthalmology. 2019 Mar;126(3):407-413. doi: 10.1016/j.ophtha.2018.07.027. Epub 2018 Aug 2.
8
Rationale and Application of the Protocol S Anti-Vascular Endothelial Growth Factor Algorithm for Proliferative Diabetic Retinopathy.协议 S 抗血管内皮生长因子算法在增生性糖尿病视网膜病变中的应用原理。
Ophthalmology. 2019 Jan;126(1):87-95. doi: 10.1016/j.ophtha.2018.08.001. Epub 2018 Aug 7.
9
Interim Safety Data Comparing Ranibizumab With Panretinal Photocoagulation Among Participants With Proliferative Diabetic Retinopathy.比较增生性糖尿病视网膜病变患者中雷珠单抗与全视网膜光凝治疗的中期安全性数据。
JAMA Ophthalmol. 2017 Jun 1;135(6):672-673. doi: 10.1001/jamaophthalmol.2017.0969.
10
Treating maculopathy at the expense of proliferative disease: an emerging problem in 'macular treatment centres'.以牺牲增殖性疾病为代价治疗黄斑病变：“黄斑治疗中心”出现的一个新问题。
Eye (Lond). 2014 Nov;28(11):1390-1. doi: 10.1038/eye.2014.160. Epub 2014 Aug 1.

引用本文的文献

1
Novel fabrication of anti-VEGF drug ranibizumab loaded PLGA/PLA co-polymeric nanomicelles for long-acting intraocular delivery in the treatment of age-related macular degeneration therapy.新型抗血管内皮生长因子药物雷珠单抗负载的聚乳酸-羟基乙酸共聚物/聚乳酸共聚物纳米胶束的制备，用于在年龄相关性黄斑变性治疗中进行长效眼内给药。
Regen Ther. 2024 Aug 27;26:620-634. doi: 10.1016/j.reth.2024.06.019. eCollection 2024 Jun.
2
Progress and Challenges of Anti-VEGF Agents and Their Sustained-Release Strategies for Retinal Angiogenesis.抗血管内皮生长因子药物及其用于抑制视网膜新生血管的持续释放策略的进展与挑战。
Drug Des Devel Ther. 2022 Sep 22;16:3241-3262. doi: 10.2147/DDDT.S383101. eCollection 2022.